<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77340">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02043145</url>
  </required_header>
  <id_info>
    <org_study_id>EPI-MULT-100</org_study_id>
    <nct_id>NCT02043145</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This post marketing surveillance study in Korea will evaluate the safety and efficacy of
      BOTOX (botulinum toxin Type A) in patients who receive treatment according to standard of
      care for primary axillary hyperhidrosis, focal spasticity or moderate to severe glabellar
      lines in clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Number of Patients with Adverse Events and Serious Adverse Drug Reactions (SADRs)</measure>
    <time_frame>4 Years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Hyperhidrosis Disease Severity Scale (HDSS) using a 4-Point Scale</measure>
    <time_frame>Pre-dose, Post-dose (Up to 4 Years)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Ashworth Scale (MAS) using a 6-Point Scale</measure>
    <time_frame>Pre-dose, Post-dose (Up to 4 Years)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator Assessment of Glabellar Line Severity using a 4-point scale</measure>
    <time_frame>Pre-dose, Post-dose (Up to 4 Years)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">727</enrollment>
  <condition>Hyperhidrosis</condition>
  <condition>Muscle Spasticity</condition>
  <condition>Glabellar Lines</condition>
  <arm_group>
    <arm_group_label>Axillary Hyperhidrosis</arm_group_label>
    <description>Patients with Axillary Hyperhidrosis who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Focal Spasticity</arm_group_label>
    <description>Patients with Focal Spasticity who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glabellar Lines</arm_group_label>
    <description>Patients with moderate or severe Glabellar Lines who are treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard of care in clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>botulinum toxin Type A</intervention_name>
    <description>Botulinum toxin Type A (BOTOX®) as prescribed according to standard of care in clinical practice.</description>
    <arm_group_label>Axillary Hyperhidrosis</arm_group_label>
    <arm_group_label>Focal Spasticity</arm_group_label>
    <arm_group_label>Glabellar Lines</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with BOTOX® (botulinum toxin Type A) as prescribed according to standard
        of care in clinical practice.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients treated with BOTOX® (botulinum toxin Type A) as prescribed according to
             standard of care in clinical practice for primary axillary hyperhidrosis, focal
             spasticity or moderate to severe glabellar lines.

        Exclusion Criteria:

          -  None.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 21, 2014</lastchanged_date>
  <firstreceived_date>January 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperhidrosis</mesh_term>
    <mesh_term>Muscle Spasticity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
